ASH 2017 | Checkpoint inhibitor/bispecific antibody combo: REGN2810 and REGN1979 in B-lymphoid malignancies
Anthony Mato
• 9 Dec 2017
Immune checkpoint inhibitors and T-cell engaging bi-specific antibodies have shown promising activity against lymphoid malignancies. In this interview, Anthony Mato, MD, MSCE, of the University of Pennsylvania, Philadelphia, PA, discusses the open-label, multicenter study of REGN2810 alone or in combination with REGN1979 (odronextamab) in patients with B-lymphoid malignancies (NCT02651662). This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
